Total Funding
72
94
Total FundingPost-IPO Debt raised
Growth Score 72 in past quarter
-14 pts
Heat Score 94 in past quarter
15 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
120
Eli Lilly is a pharma company focused on developing medicines for diabetes, cancer, immunology, and other major health areas.
Marie Murphy: Principal Research Scientist, Technical Services Manufacturing Network- Ronald DeMattos: Senior Vice President and Chief Scientific Officer Neurobiologics
About the Company
Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts
research to find products to treat diseases in animals and to increase the efficiency of animal food production.


